Analysts Wells Fargo recommend buying Progyny (PGNY) shares with a target price of $37, indicating 45% upside
Wells Fargo's initiation of coverage on Progyny with an overweight rating and a $37 price target indicates strong potential for growth in the fertility benefits management sector, suggesting a 45% upside for investors.